Company founder and inventor of photokinetic technology broadly covering the application of biologically active substances on the skin and cellular membranes in conjunction with visible and near infrared light illumination to facilitate topical permeation and increase light absorption. The technology family is covered by six issued patents and other patents pending

DermaKinetics®, the skincare brand of PhotoKinetix Holdings, Inc., is the only patented system combining light therapy with bioactive compounds to improve topical infusion for at-home, spa, salon and professional applications. DermaKinetics® topical infusion systems are engineered for skincare, haircare, scalp care, oral care and pain management.PhotoKinetix skincare is marketed under the DermaKinetics® trademark. https://photokinetix.com/DermaKinetics patented topical skincare is designed to work with light therapy to reduce oxidative stress, eliminate inactive cells with senolytic compounds and regenerate healthy skin. DermaKinetics® patented, water-resistant, Topical Actuator is engineered to increase infusion of bioactive ingredients in serums, facial masks, facial sheet masks and skin patches while maintaining the integrity of the stratum corneum. DermaKinetics® patented technology infuses the delivery of antioxidants, phytonutrients, peptides, growth factors, stilbenoids, phytochemicals, senolytics, vitamins, essential oils, hyaluronic acid and anti-inflammatories for improved efficacy while stimulating cell regeneration. DermaKinetics® is the only LED topical infusion system that enhances the powerful properties of CBD for high-performance skincare, pain management, oral care and scalp/hair care.DermaKinetics Skincare Systems covered under US9474911 Kraft E et al.: Delivery of Large Molecular Weight Biologically Active Substances.

Composition development and light device engineering for patented and patent pending vaginal rejuvenation systems. The FemWell systems are intended for use by pre and post-menopausal women to treat vaginal dryness, atrophic vaginitis and various vaginal conditions. The systems are designed to promote sexual wellness and health benefits.

Development of various drug delivery technologies pursuant to commercialization. Areas of interest: • Scalable cyclodextrin inclusion technology of small molecule Chemical Class II water-insoluble compounds including essential oils, plant polyphenols and cannabidiol for substantially increased water solubility and bio-availability without surfactants or co-solvents.• Antibody anti-aggregation composition development for therapeutics and diagnostics.• Topical eye drop ocular delivery and inhaled pulmonary drug delivery.• Composition and device configurations for skin, vaginal, ocular and pulmonary drug delivery.Please see a full list of published work at National Center for Biotechnology Information (NCBI) Link:https://www.ncbi.nlm.nih.gov/myncbi/1Pqqx6lPawnk8/bibliography/public/

Developed viscous liquid aerosol delivery platform to treat smoke inhalation in experimental intensive care unit. Developed a large dose powdered drug delivery system to treat cardiac arrest. Developed antibody and protein therapeutics anti-aggregation technology to deliver monomer antibody forms for both noninvasive topical ocular delivery and aerosol pulmonary delivery. Developed cyclodextrin-based water soluble polyphenol topical compositions to treat ocular injury and inflammation. Technology developments lead to three issued and one patent pending.